Communiqués Gyre Therapeutics, Inc.

Actions

GYRE

US4037831033

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
7,080 ^USD	-3,67%		-3,28%	+0,28%

07/08	Gyre Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
07/08	Gyre Therapeutics, Inc. confirme ses prévisions de résultats pour l'exercice 2026	CI

Communiqués

03/09	Gyre Therapeutics to Participate in Upcoming September Investor Conferences	GL
07/08	Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update	GL
16/07	Gyre Therapeutics Appoints Three New Members to its Board of Directors	GL
12/05	Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment	GL
07/05	Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update	GL
07/05	Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update	AQ
06/05	Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company	AQ
04/05	Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company	GL
17/03	Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment	GL
17/03	Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment	AQ
12/03	Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
02/03	Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline	AQ
27/01	Gyre Therapeutics : Corporate Presentation January 2026 955.1 KB	PU
05/01	Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting	GL
07/11	Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update	GL
15/10/25	Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis	GL
14/10/25	Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025	GL
10/09/25	Gyre Therapeutics : H.C. Wainwright Global Investment Conference Presentation – September 2025 916.4 KB	PU
05/09/25	Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	GL
22/08/25	Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors	GL
21/08/25	Gyre Therapeutics : Corporate Presentation August 202	PU
11/08/25	Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update	GL
10/06/25	Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China	GL
10/06/25	Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China	AQ
29/05/25	Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	GL